Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Accumulated Expenses (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Accumulated Expenses for 13 consecutive years, with $7.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 1.22% to $7.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.7 million, a 1.22% decrease, with the full-year FY2025 number at $7.7 million, down 1.22% from a year prior.
  • Accumulated Expenses was $7.7 million for Q4 2025 at Niagen Bioscience, down from $8.7 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $10.5 million in Q1 2024 to a low of $5.6 million in Q2 2021.
  • A 5-year average of $8.0 million and a median of $8.1 million in 2023 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: surged 36.07% in 2023, then decreased 17.66% in 2024.
  • Niagen Bioscience's Accumulated Expenses stood at $6.5 million in 2021, then grew by 13.21% to $7.3 million in 2022, then rose by 29.39% to $9.5 million in 2023, then decreased by 17.66% to $7.8 million in 2024, then decreased by 1.22% to $7.7 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Accumulated Expenses are $7.7 million (Q4 2025), $8.7 million (Q3 2025), and $7.4 million (Q2 2025).